Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed Tuesday that animal tests show the company’s DehydraTECH technology combined with generic nanotech techniques delivers more than ten times the amount of cannabidiol (CBD) to the brain.
DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.
The Kelowna, British Columbia company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.
DehydraTECH with generic nanotech techniques now delivers 1,137% more CBD into animal brain tissues, said the company in a statement following oral ingestion than other existing industry formulations.
READ: Lexaria’s DehydraTECH formulation delivers CBD to bloodstream quicker than conventional industry formulations
On March 20, Lexaria started running animal tests with multiple objectives that included developing a better understanding of how effectively edible forms of CBD cross the blood-brain-barrier.
In this arm of the study, Lexaria combined its DehydraTECH delivery technology with standard nanotechnology to analyze how quickly CBD was delivered into an animal’s brain tissues following oral ingestion.
Lexaria earlier carried out two series of animal tests in 2018 that proved that its DehydraTECH delivers nicotine across the blood-brain-barrier more effectively than industry standards. This new study seeks to build on the premise whether this holds true for cannabinoids. Derived from hemp, CBD does not contain the psychoactive compounds found in cannabis.
Lexaria also tested for differences in brain delivery rates between its patented long chain fatty acid CBD formulations without nanotech processing with those of medium chain triglycerides (MCT) oils.
Encouraging test results
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were orally administered CBD at the rate of 25 milligram per kilogram of bodyweight. Delivery of CBD into the brain was reported 8 hours after dosing.
In working with nanoemulsion processing equipment, Lexaria has developed a method to combine DehydraTECH with nanoemulsification for specific performance applications. Lexaria does not work with inorganic materials for purposes of nano-transformation since inorganic materials manipulated with nanotech have at times indicated poor health outcomes in animal testing. Lexaria's patented formulations rely solely on safe organic ingredients.
Lexaria’s DehydraTECH long chain fatty acid formulation without nanotech achieved an average brain tissue accumulation level that was 246% higher than the average for those animals that received the MCT oil formulation.
On the other hand, the DehydraTECH long chain fatty acid formulation with nanotech achieved an average brain tissue accumulation level that was 1,137% higher than the average for those animals that received the MCT oil formulation.
A series of animal tests conducted in 2018 and 2019 have already shown DehydraTECH to greatly assist the delivery of nicotine and cannabinoids across the blood-brain-barrier.
The effectiveness of DehydraTECH together with nanoemulsification now greatly expands the applicability of Lexaria’s technology both for conventional edible dosage, consumable liquid and beverage dosage forms.
The company said it will make its new technological advances available to its licensed corporate clients in North America through license agreements as rapidly as it is possible to customize each unique client formulation.
Lexaria said its wholly owned subsidiary Lexaria Pharmaceutical will pursue the technology’s opportunities outside of cannabinoids and nicotine to encompass other drug classes.
Contact Uttara Choudhury at [email protected]